{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-010869","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.430127+00:00","generated_at":"2026-06-25T06:25:09.987060+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Relay Therapeutics stockholders approve doubling authorized common stock to 300M shares","bullets":["Shareholders approved amendment to increase authorized common shares from 150M to 300M (93,032,987 for, 758,293 against).","Directors elected: Alexis Borisy, Mark Murcko, Laura Shawver (class II, three-year term).","Non-binding advisory vote on executive compensation passed (83,645,401 for, 3,551,366 against).","Ratification of Ernst & Young as independent auditor for FY2022 approved (93,772,475 for, 15,739 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-010869","json":"https://secwatch.observer/filing/0000950170-22-010869.json","markdown":"https://secwatch.observer/filing/0000950170-22-010869.md","text":"https://secwatch.observer/filing/0000950170-22-010869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022010869/0000950170-22-010869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022010869/rlay-20220527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T06:25:09.987060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}